Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
SANTA MONICA, Calif., Feb. 17, 2016 -- Lightlake Therapeutics Inc. (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that it has changed the company name to Opiant Pharmaceuticals, Inc. (“Opiant”).
“2015 was a transformational year for our company driven by our partner’s approval of our first product now branded as NARCAN® Nasal Spray,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Therefore, we viewed this transformation as an opportunity to give the company a name that better represents our historical core focus of opioid antagonist treatments.”
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. by the company’s partner, Adapt Pharma Limited. Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near term focus on cocaine use disorder and binge eating disorder (BED). For more information please visit: www.opiant.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT INFORMATION: Corporate Contact: [email protected] Media Relations: Robert E. Flamm, Ph.D. [email protected] (212) 845-4226
